|1.||Curnow, Alison: 4 articles (12/2013 - 01/2007)|
|2.||Blake, Emma: 2 articles (12/2013 - 09/2010)|
|3.||Campbell, S M: 2 articles (01/2010 - 08/2008)|
|4.||Curnow, A: 2 articles (01/2010 - 08/2008)|
|5.||Pye, Andrew: 2 articles (08/2008 - 01/2007)|
|6.||Allen, James: 1 article (12/2013)|
|7.||Manalo, Dominador J: 1 article (04/2011)|
|8.||Hider, Robert C: 1 article (04/2011)|
|9.||Baek, Jin Hyen: 1 article (04/2011)|
|10.||Reiter, Chad E N: 1 article (04/2011)|
10/01/1994 - "Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94."
02/01/1999 - "Desferrioxamine and CP94 (1,2-diethyl-3-hydroxypyridin-4-one) are metal chelators used or proposed for use in the clinical treatment of iron overload. "
04/01/1995 - "The chronic polyploidizing effect of iron overload alone was investigated further and shown to be proportional to the dose and was detectable as early as 2 days after 600 mg Fe/kg and 1 week after 150 mg Fe/kg. Polyploidization of nuclei was inhibited by the oral iron chelator CP94. "
09/25/1992 - "The oral efficacy of the oral iron chelators 1,2-dimethyl-3-hydroxypyrid-4-one (CP20), 1,2-diethyl-3-hydroxypyrid-4-one (CP94) and desferrioxamine B (DFO) has been compared with intraperitoneal DFO in an experimental model of iron overload with similar biochemical and biophysical characteristics to those observed for human genetic haemochromatosis. "
|2.||Basal Cell Carcinoma (Rodent Ulcer)
08/01/2008 - "Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma."
01/01/2010 - "Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: further explanation of a dose-escalating pilot study conducted primarily to consider the safety of this pharmacological modification."
07/01/2009 - "Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: when statistics make a difference."
08/01/2008 - "Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma."
11/01/1998 - "PDT studies conducted on the colonic mucosa showed that the simultaneous administration of 100 mg kg(-1) CP94 i.v. and 50 mg kg(-1) ALA i.v. produced an area of necrosis three times larger than similar parameters without the iron-chelating agent with the same light dose. "
11/01/1998 - "It is possible, therefore, to increase the amount of necrosis produced by ALA-induced PDT substantially, without increasing the administered dose of ALA, through the simultaneous administration of the iron-chelating agent, CP94."
09/01/2010 - "The use of CP94 in combination with ALA/MAL produced significant enhancements of PpIX fluorescence in human glioma cells. "
09/01/2010 - "It is therefore concluded that with further study CP94 may be a useful adjuvant to photodiagnosis and/or PpIX-induced PDT treatment of glioma."
09/01/2010 - "This study analyzed the effects of ALA/MAL-induced PDT combined with the iron chelator 1, 2-diethyl-3-hydroxypyridin-4-one hydrochloride (CP94) on the accumulation of PpIX in human glioma cells in vitro. "
09/01/2010 - "The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells."
|5.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/01/2007 - "In vitro studies investigated the efficacies of the novel iron chelator, CP94 (1,2-diethyl-3-hydroxypyridin-4-one hydrochloride), and the established iron chelator, desferrioxamine (DFO), at increasing PPIX fluorescence in cultured human lung fibroblasts and squamous carcinoma cells incubated with ALA/MAL. "
|9.||Aligeron (AS 2)
|1.||Photochemotherapy (Photodynamic Therapy)